Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: WeirdPro Randy who wrote (1262)	8/28/1998 10:45:00 AM
From: David Bauerle	Read Replies (1) \| Respond to of 1359

Do you think American Home will possibly market Redux once again, or has public sentiment, and the current litigation put Redux away forever? It's a shame that public misuse of Redux, completely destroyed this stock. I assume that even though the evidence appears to clear IPIC from liability the lawsuits will still continue, and public sentiment will empathize with the plaintiffs. It's also a shame I don't have the confidence that our judicial system can overlook the emotion, and make judgement only on the evidence Your report is great news, but if it doesn't produce the lost revenue, and doesn't eliminate the lawsuits and possible liability, the apparent positive finding for American Home may not have much of an impact on the finicial success of IPIC.

To: WeirdPro Randy who wrote (1262)	8/30/1998 7:01:00 AM
From: jlib	Read Replies (1) \| Respond to of 1359

In all of this, why has no one gone back to Michael Weintraub's patients of the late 80's-early 90's whose participation in a four year study first proved the effectiveness of the fen-phen combination? It seems they would be the most fruitful group to investigate for any long term effects. Wurtman's protestation that "They should never have been prescribed together" is a bit disingenuous. Does anyone remember IPIC releasing any memos to physicians discouraging that use? Also, even if we bracket out the fact that both Wurtman and the coauthor are on IPIC's payroll, his attempt to label phentermine and such things as Sudafed as effective MAO inhibitors in humans at common dosage levels is simply not credible. Best, Jimmy Liberato